Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $55.00

Dianthus Therapeutics (NASDAQ:DNTH) had its target price boosted by Wedbush from $46.00 to $55.00 in a report published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also weighed in on DNTH. Jefferies Financial Group boosted their price objective on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $67.63.

Dianthus Therapeutics Trading Down 0.2%

DNTH stock opened at $47.40 on Wednesday. The firm has a 50-day moving average of $45.01 and a two-hundred day moving average of $37.04. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $57.50. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -13.62 and a beta of 1.59.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP lifted its holdings in shares of Dianthus Therapeutics by 76.0% in the 4th quarter. Marshall Wace LLP now owns 1,008,533 shares of the company’s stock worth $41,562,000 after acquiring an additional 435,595 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Dianthus Therapeutics by 36.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 25,598 shares of the company’s stock valued at $1,050,000 after purchasing an additional 6,816 shares during the period. Walleye Capital LLC raised its position in Dianthus Therapeutics by 45.8% in the fourth quarter. Walleye Capital LLC now owns 205,815 shares of the company’s stock valued at $8,482,000 after purchasing an additional 64,686 shares during the period. Quarry LP acquired a new position in Dianthus Therapeutics during the fourth quarter worth $99,000. Finally, Public Sector Pension Investment Board purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth $1,998,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.